Professor Shusen Wang: New ADC Drugs Leading the Way in Treating HER2-Low Breast Cancer | 2024 National Breast Cancer Conference

Professor Shusen Wang: New ADC Drugs Leading the Way in Treating HER2-Low Breast Cancer | 2024 National Breast Cancer Conference

With the success of antibody-drug conjugates (ADCs) in treating HER2-low breast cancer patients, this patient group is receiving increased attention. The latest 2024 CSCO BC guidelines were released on April 12 in Beijing, featuring the first recommendations for treating HER2-low patients. "Oncology Frontier" invited Professor Shusen Wang from Sun Yat-sen University Cancer Center to discuss the current treatment landscape for HER2-low patients and the recommendations in the 2024 CSCO BC guidelines.
2024 ESMO BC丨Professor Qiang Liu: Clinical Trials and Real-World Data Complement Each Other to Provide Optimal Treatment for Breast Cancer Patients

2024 ESMO BC丨Professor Qiang Liu: Clinical Trials and Real-World Data Complement Each Other to Provide Optimal Treatment for Breast Cancer Patients

At the 2024 ESMO BC conference, Professor Qiang Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, presented a report titled "From Phase III Clinical Trials to Real-World Data: Bridging the Gap Between Clinical Trials and Clinical Practice." This report delved into the treatment advances for HER2-positive breast cancer, the differences between clinical trials and real-world data, and how to better guide clinical practice. "Oncology Frontier" invited Professor Liu to share insights on his report and the disparities between clinical trials and clinical practice.
2024 ESMO BC丨Professor Hope S. Rugo: Breast Cancer Research – Lessons from the Past Will Shape the Future

2024 ESMO BC丨Professor Hope S. Rugo: Breast Cancer Research – Lessons from the Past Will Shape the Future

t the 2024 ESMO BC conference, Professor Hope S. Rugo, the recipient of the 2024 ESMO Breast Cancer Award, reflected on the current challenges in the field of breast cancer during her speech. After working in the field of malignant hematology for nine years, Professor Hope S. Rugo's mother was diagnosed with metastatic breast cancer, prompting her to transition to breast cancer research and clinical practice. It was a difficult time for cancer patients, with limited treatment options, unfocused care, poor management of side effects, and no end-of-life support. Today, Hope S. Rugo is a Professor of Medicine at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), and she has been awarded the 2024 ESMO Breast Cancer Award for her outstanding contributions to improving treatment options for future generations of breast cancer patients. Her desire to honor her mother has always been behind her professional achievements.
EBMT Exclusive Interview | Professor Yanmin Zhao: Maintenance Treatment Strategies for FLT3-ITD Mutant AML Patients After Transplantation

EBMT Exclusive Interview | Professor Yanmin Zhao: Maintenance Treatment Strategies for FLT3-ITD Mutant AML Patients After Transplantation

FMS-like tyrosine kinase 3 (FLT3) mutations, particularly internal tandem duplication mutations (FLT3-ITD), are one of the significant factors affecting the prognosis of patients with acute myeloid leukemia (AML). Overcoming the challenge of relapse after transplantation in patients with FLT3-mutated AML remains a significant clinical hurdle. At the 50th European Bone Marrow Transplantation (EBMT) annual meeting, Professor Yanmin Zhao from The First Affiliated Hospital of Zhejiang University School of Medicine presented a study (Abstract No.: OS18-08), which explored the impact of mutations in myelodysplasia-related (MR) genes on maintenance treatment outcomes after transplantation for FLT3-ITD AML patients. "Oncology Frontier - Hematology Frontier" invited Professor Yanmin Zhao to share insights into the maintenance treatment strategies, challenges, and future research directions for FLT3-ITD mutant AML patients after transplantation.
Professor Hongyuan Li : Discussing the Forefront of Subcutaneous Mastectomy and Reconstruction, Building New Peaks of Beauty for Patients | 2024 SFBCS

Professor Hongyuan Li : Discussing the Forefront of Subcutaneous Mastectomy and Reconstruction, Building New Peaks of Beauty for Patients | 2024 SFBCS

May 31, 2024Open Immersive ReaderEditor's Note: From April 19 to April 20, 2024, the 11th Sino-French (International) Advanced Breast Cancer Forum (SFBCS) was grandly held in Chongqing, where domestic and international experts shared vital content on basic breast cancer research, pathology diagnostics, surgical operations, and systemic treatment. In the surgical session, Professor Hongyuan Li from The First Hospital affiliated with Chongqing Medical University analyzed the "hot issues in subcutaneous mastectomy combined with breast reconstruction" based on his real-case follow-up experiences. "Oncology Frontier" took this opportunity to interview Professor Li on-site, providing guidance on breast reconstruction.
Professor Hong You: Striving to Link the “Beijing Standard” for Cirrhosis Reversal with Reduced Incidence of Cirrhosis Decompensation and Liver Cancer

Professor Hong You: Striving to Link the “Beijing Standard” for Cirrhosis Reversal with Reduced Incidence of Cirrhosis Decompensation and Liver Cancer

Under long-term and repeated stimulation from various causes, a normal liver can develop into cirrhosis. Histologically, cirrhosis is characterized by diffuse liver fibrosis accompanied by collapse of the lobular structure (including microvascular structures) and the formation of pseudolobules, leading to portal hypertension and even liver function decompensation. Professor Hong You's team at Beijing Friendship Hospital, Capital Medical University, was the first in the world to propose a new pathological standard for evaluating the reversal of hepatitis B-induced cirrhosis. This new standard, known internationally as the "Beijing Standard," not only increases the recognition rate of cirrhosis reversal but also changes the clinical practice of requiring two liver biopsies for evaluation. Recently, at the "25th National Academic Conference on Traditional Chinese Medicine for Hepatobiliary Diseases," Hepatology Digest conducted an exclusive interview with Professor Hong You to discuss the diagnosis of cirrhosis reversal and other related issues. Here are the highlights of the interview.
Professor Yueqiu Gao: Combining Existing Treatments with Traditional Chinese Medicine Can Improve the Prognosis of Liver Cirrhosis Patients, But Further Research is Needed

Professor Yueqiu Gao: Combining Existing Treatments with Traditional Chinese Medicine Can Improve the Prognosis of Liver Cirrhosis Patients, But Further Research is Needed

According to statistics, there are currently over 400 million people in China suffering from various liver diseases, with approximately one in three people having chronic liver disease. Hepatitis B patients account for about 24% of this number. Liver diseases have become one of the most prevalent threats to people's health. Chronic liver diseases, such as chronic viral hepatitis, liver cirrhosis, and non-alcoholic fatty liver disease, if not treated in a timely and standardized manner, can eventually progress to liver failure or even liver cancer, posing a serious threat to human life and health. With the advancement of medicine, the integration of traditional Chinese and Western medicine in China has opened new avenues for the diagnosis and treatment of chronic liver diseases by complementing each other's strengths. Recently, at the 25th National Academic Conference on Traditional Chinese Medicine for Hepatobiliary Diseases organized by the Hepatobiliary Disease Branch of the Chinese Association of Traditional Chinese Medicine, Professor Yueqiu Gao addressed the advantages and shortcomings of traditional Chinese medicine in treating chronic hepatitis. Hepatology Digest has compiled this discussion for its readers.
EAU24 China’s Voice丨Professor Qiang Wei and Professor Lu Yang’s Team Shine at EAU Conference, Leading Multiple Studies at the International Frontier

EAU24 China’s Voice丨Professor Qiang Wei and Professor Lu Yang’s Team Shine at EAU Conference, Leading Multiple Studies at the International Frontier

The 39th Annual European Association of Urology (EAU) Conference was grandly held from April 5th to 8th, 2024, in Paris, France. As a top-tier event in the global field of urology, the EAU Conference gathered numerous experts and scholars in the urology field to discuss cutting-edge advancements and future trends in urology. At this year's EAU Conference, Professor Qiang Wei and Professor Lu Yang's research team from West China Hospital of Sichuan University had multiple studies selected, representing the latest developments in urology in China and contributing significantly to the global advancement of urology. The "Oncology Frontier" magazine has compiled the relevant research below for readers' enjoyment.